Pfizer to study COVID-19 treatment in children

Marzo 9, 2022

Pfizer Inc. announced on Wednesday that it will start a “Phase 2/3 study” of its Paxlovid coronavirus treatment in children aged 6 to 17.

The children will be divided into two groups separated by wei…